Publications Angelica Loskog

Publications in DiVA

Publications in PubMed

Selected publications:

  1. Liljenfeldt, L., Dieterich, L., Dimberg, A., Mangsbo, S., Loskog, A.S. CD40L inhibits recruitment of myeloid-derived suppressor cells (MDSC) to the tumor micro milieu. Cancer Gene Ther. 2014, 21:95-102.
  2. Liljenfeldt, L., Gkirtzimanaki, K., Vyrla, D., Svensson, E., Loskog, A., Eliopoulos, A. Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand. Cancer Immunol Immunother. 2014, 63:273-282.
  3. Westberg, S., Sadeghi, A., Svensson, E., Segall, T., Dimopoulou, M., Korsgren, O., Hemminki, A., Loskog, S.I.A., Tötterman, T.H., von Euler, H.Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J Immunother. 2013, 36:350-358.
  4. Karlsson, H.S.C., Lindqvist, C.A., Fransson, M., Paul Wetterberg, G., Nilsson, B., Essand., Nilsson, K., Frisk, P., Jernberg-Wiklund, H., Loskog, S.I.A. ABT-737 blockade of Bcl-2 family apoptosis inhibitors sensitizes B cell tumors to CAR T cell killing. Cancer Gene Ther. 2013, 20:386-393.
  5. Burman, J., Fransson, M., Tötterman, TH., Fagius, J., Mangsbo, SM., Loskog, ASI. Immune reconstitution after hematopoietic stem cell transplantation for MS. Immunology. 2013, 140:211-219.
  6. Fransson, M., Piras, E., Burman, J., Nilsson, B., Essand, M., BinFeng, L., Harris, R.A., Magnusson, P.U., Brittebo, E., Loskog, A.S.I. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation. 2012, 9:112.
  7. Diaconu, I., Cerullo, V., Hirvinen, M.L., Escutenaire, S., Ugolini, M., Pesonen, S.K., Bramante, S., Parviainen, S., Kanerva, A., Loskog, A., Eliopoulos, A., Pesonen, S., Hemminki, A. Immune response is an important aspect of the anti-tumor effect of an oncolytic adenovirus coding for CD40L. Cancer Res. 2012, 72:2327-2338.
  8. Lindqvist, C., Christiansson, L., Thörn, I., Mangsbo, S., Wetterberg, G., Sundström, C., Tötterman, T.H., Simonsson, B., Enblad, G., Frisk, P., Olsson-Strömberg, U., and Loskog, A. Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology. 2011, 133:296-306.
  9. Lindqvist, C.A., Christiansson, L.H., Simonsson, B., Enblad, G., Olsson-Stromberg, U., Loskog, S.I.A. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology. 2010, 131:371-376.
  10. *Malmström, P-U., *Loskog, A., Lindqvist, C., Mangsbo, S., Fransson, M., Wanders, A., Gårdmark, T., Tötterman, T.H. AdCD40L immunogene therapy for bladder carcinoma – the first phase I/IIa trial. Clin Cancer Res. 2010, 16:3279-3287. *contributed equally to this work.